Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

CEL-SCI ($CVM) reported receiving a new patent from the European Patent Office. The new patent pertains to its lead product candidate Multikine (Leukocyte Interleukin, Injection), an immunotherapy in development for certain head and neck cancers and peri-anal warts and cervical dysplasia in patients co-infected with HIV and HPV. The company's Phase 3 study in head and neck cancer is currently on clinical hold by the FDA while it addresses issues with the Investigator's Brochure and protocol.
The company stock gained over 21 percent in its previous trading session, trimming its 12 months losses to 77 percent. The stock gained 80 percent this year so far.

Bristol Myers Squibb ($BMY) announced receiving approval from the Chinese authorities for its all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country. The treatment combines two antiviral drugs, daclatasvir and asunaprevir, for use against a type of hepatitis C known as genotype 1b. This type is the most prevalent one in China. The company has also received the approval for using daclatasvir in combination with other drugs to treat more types of the disease.
The company stock has lost 22 percent of its value in the past 12 months while its Year to Date loss stands at 4 percent.

 
Intra-Cellular Therapies ($ITCI) announced that the FDA has asked for more information on findings observed in nonclinical animal toxicology studies of lumateperone. The company said that it is preparing responses to the FDA’s request for additional information and intend to proceed with its long-term safety study of lumateperone in patients with schizophrenia.
 
Alkermes ($ALKS) announced that it has completed patient enrollment in ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN clinical development program for ALKS 3831. The multinational, randomized, double-blind phase 3 study is designed to evaluate the antipsychotic efficacy of ALKS 3831 compared to placebo over four weeks in patients experiencing an acute exacerbation of schizophrenia.

Bristol Myers Squibb ($BMY) receives the European Commission’s approval for Opdivo (nivolumab) for the treatment of adult patients with squamous cell cancer of the head and neck who are progressing on or after platinum-based chemotherapy. The advisory committee CHMP adopted a positive opinion backing approval a month ago.

Takeda Pharmaceutical ($TKPYY) announced receiving the FDA approval for Alunbrig (brigatinib) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer who have progressed on or are intolerant of crizotinib.

 

AmerisourceBergen Corporation ($ABC) announced a new collaboration with Express Scripts. Under the terms of this deal, AmerisourceBergen will supply pharmaceuticals to Express Scripts. The agreement is effective for five years and extends  a supply agreement between the two companies through September 30, 2022. The collaboration contributed approximately $23 billion in FY16 revenue.

 
The Ensign Group Inc. ($ENSG) announced its first quarter results as the company reported its adjusted earnings at $0.34 per share. Its same store skilled mix revenue grew by 5.1% over the prior quarter to $120.9 million. The company’s same store managed care revenue for the transitional and skilled nursing segment grew by 11.0% over the prior quarter to $42.1 million.
Radius Health Inc. ($RDUS) reported its quarter net loss at $56.9 million, or $1.32 per share, as compared to a net loss of $40.5 million, or $0.94 per share, for the quarter ended March 31, 2016.  Its Research and development expenses for quarter stood at $19.5 million, compared to $27.5 million it spent during the corresponding quarter of the previous year.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Rodman & Renshaw
Initiates
Aduro BioTech (ADRO)
Buy -> Buy
$18.00
Low
Benchmark
Lowers Target
Natus Medical (BABY)
Buy
$55.00 -> $48.00
N/A
Cowen and Company
Reiterates
Baxter International (BAX)
Market Perform
$48.00 -> $57.00
Low
BTIG Research
Reiterates
bluebird bio (BLUE)
Buy

Low
JPMorgan Chase & Co.
Reiterates
BioMarin Pharmaceutical (BMRN)
Buy

Low
Leerink Swann
Initiates
Audentes Therapeutics (BOLD)
Outperform

Low
BTIG Research
Reiterates
Celgene (CELG)
Buy
$138.00
Low
Barclays PLC
Reiterates
Cerner (CERN)
Hold
$60.00
Low
Canaccord Genuity
Reiterates
Cerner (CERN)
Buy
$59.00 -> $66.00
Low
Credit Suisse Group AG
Downgrades
Corvus Pharmaceuticals (CRVS)
Outperform -> Underperform
$10.00
Low

Gainers (% price change) Last Trade Change Mkt Cap
Invacare Corporation IVC 14.70 +1.45 (10.94%) 489.12M
Merit Medical Systems MMSI 33.70 +2.50 (8.01%) 1.68B
HealthSouth Corp HLS 46.90 +3.40 (7.82%) 4.18B
Cerner Corporation CERN 64.75 +4.69 (7.81%) 21.58B
Regeneron Pharmaceuticals REGN 388.49 +21.87 (5.97%) 40.76B
Losers (% price change)
Abaxis Inc ABAX 45.03 -4.32 (-8.75%) 1.02B
Gen-Probe Incorporated 8.25 -0.69 (-7.72%) 1.16B
ResMed Inc. RMD 67.99 -4.86 (-6.67%) 9.78B
LeMaitre Vascular Inc LMAT 29.75 -2.11 (-6.62%) 671.98M
ZIOPHARM Oncology Inc. ZIOP 7.04 -0.47 (-6.26%) 940.70M
Most Actives (dollar volume)
Regeneron Pharmaceuticals REGN 388.49 +21.87 (5.97%) 40.76B
Becton Dickinson and Co BDX 186.97 +4.48 (2.45%) 40.40B
Cerner Corporation CERN 64.75 +4.69 (7.81%) 21.58B
Merck & Co., Inc. MRK 62.33 -0.25 (-0.40%) 170.55B
C R Bard Inc BCR 307.48 +1.68 (0.55%) 22.37B